- ￥2175
- Sigma-Aldrich
- 进口
- T1573-5MG
- 2025年08月13日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
−20°C
- 保质期：
根据瓶身LOT号查询
- 英文名：
Thrombin Receptor Activator Peptide 6
- 库存：
有现货
- 供应商：
浙江羽翔生物科技有限公司
- CAS号：
141136-83-6
- 规格：
5MG
属性
质量水平
200
方案
>95% (HPLC)
表单
lyophilized
技术
cell culture | mammalian: suitable
溶解性
0.1% TFA: soluble
water: soluble
UniProt登记号
P25116
储存温度
−20°C
SMILES字符串
CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O
InChI
1S/C34H56N10O9/c1-18(2)13-23(30(49)40-22(11-8-12-39-34(37)38)29(48)44-26(33(52)53)16-27(36)46)42-31(50)24(14-19(3)4)43-32(51)25(41-28(47)21(35)17-45)15-20-9-6-5-7-10-20/h5-7,9-10,18-19,21-26,45H,8,11-17,35H2,1-4H3,(H2,36,46)(H,40,49)(H,41,47)(H,42,50)(H,43,51)(H,44,48)(H,52,53)(H4,37,38,39)/t21-,22-,23-,24-,25-,26-/m0/s1
InChI key
HAGOWCONESKMDW-FRSCJGFNSA-N
基因信息
human ... F2R(2149)
Amino Acid Sequence
一般描述
应用
生化/生理作用
其他说明
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Inhibition of Dendritic Cell Activation and Modulation of T Cell Polarization by the Platelet Secretome.
Platelet transfusions are a frequently administered therapy for especially hemato-oncological patients with thrombocytopenia. Next to their primary function in hemostasis, currently there is increased attention for the capacity of platelets to affect the function of various cells of the immune system. Here, we investigate the capacity of platelets to immuno-modulate monocyte-derived dendritic cells (moDC) as well as primary dendritic cells and effects on subsequent T cell responses. Platelets significantly inhibited pro-inflammatory (IL-12, IL-6, TNFα) and increased anti-inflammatory (IL-10) cytokine production of moDCs primed with toll-like receptor (TLR)-dependent and TLR-independent stimuli. Transwell assays and ultracentrifugation revealed that a soluble factor secreted by platelets, but not microvesicles, inhibited DC activation. Interestingly, platelet-derived soluble mediators also inhibited cytokine production by human ex vivo stimulated myeloid CD1c+ conventional DC2. Moreover, platelets and platelet-derived soluble mediators inhibited T cell priming and T helper differentiation toward an IFNγ+ Th1 phenotype by moDCs. Overall, these results show that platelets are able to inhibit the pro-inflammatory properties of DCs, and may even induce an anti-inflammatory DC phenotype, with decreased T cell priming capacity by the DC. The results of this study provide more insight in the potential role of platelets in immune modulation, especially in the context of platelet transfusions.
【参考值】 凝血酶原：83%～127% 因子V：50%～150% 因子VII：65%～135% 因子X：45%～155% 【临床意义】 将病人血浆分别与测定凝血酶原基质血浆（人工制备凝血酶原血浆），测定因子V用的基质血浆（储存血浆或先天性因子V缺乏症患者血浆，凝血酶原时间测定应>1分钟），测定因子VII用的基质血浆（先天性因子VII缺乏症患者的血浆。基质血浆也可采用先天性因子VII缺乏症患者血浆与正常人硫酸钡吸附血浆等量混合），测定因子X
[资源][原创] 蛋白标签纯化技术——CBP（钙调蛋白结合肽）
基于ＣＢＰ标签技术的蛋白质表达与纯化系统 （用于高水平蛋白质表达和单步骤纯化）Protein Expression and Purification System是一种简单、温和、有效的方法，包括一个含有 calmodulin-binding peptide tag 钙调蛋白结合肽标签的pCAL 表达载体和一个用于分离的钙激酶亲合树脂，可快速敏感的捕捉标签融合蛋白。T7 RNA polymerase-based pCAL 载体能够快速克隆钙调蛋白结合肽标签融合蛋白。CBP标记的蛋白在低浓度钙
后的目标蛋白产量范围在1.5-100mg/L。趋化因子和细胞因子可以得到高达30-100mg/L的产量。其它关于这些蛋白表达和纯化的有参考价值信息包括： ■ 植物磷酸烯醇式丙酮酸—羧化酶激酶（Ermolova 2003）——目标蛋白切除标签后用BDA（蓝色葡聚糖）亲和层析树脂纯化。纯化后蛋白的催化活性比未切除标签的融合蛋白高50倍。 ■ Xklp3a，Tep3Ag和E8R（De Marco 2004）——用蛋白酶切割后，His-融合的TEV和NusA被Ni2+离子亲和色谱选择性去除
技术资料暂无技术资料 索取技术资料
